N-Acetyl Cysteine in the Prevention of Contrast Induced Nephropathy in Cirrhosis of Liver-NEPHRO Trial
Status:
Completed
Trial end date:
2019-01-15
Target enrollment:
Participant gender:
Summary
Contrast induced nephropathy has an incidence of 7-11 % in patients undergoing Contrast
imaging for various conditions. The risk associated with the development of CIN are still
under evaluation. Even with patients having normal kidney functions there is a risk of
contrast induced nephropathy hence the need for markers which could predict injury. Cirrhosis
of liver predisposes patient to Kidney abnormalities as these patients lower renal reserve
and can have various conditions like Hepatorenal syndrome, Sepsis, ATN. Contrast imaging is
vital for ruling out conditions like Hepatocellular Carcinoma in patients of cirrhosis of
liver. Presently there is no study in cirrhosis of liver which studies the Effect of N-acetyl
cysteine before and after contrast imaging in the prevention Of CIN. The incidence of CNI is
cirrhosis is also an avenue which requires more studies and also there is a need for
formulation of a Score to predict this CIN. Hence this study is being done to assess the
incidence of CNI and the role of N-Acetyl cysteine in Preventing CNI.